We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Prevalence and Risk Factors for Hyposalivation and Xerostomia in Childhood Cancer Survivors Following Different Treatment Modalities—A Dutch Childhood Cancer Survivor Study Late Effects 2 Clinical Study (DCCSS LATER 2).
- Authors
Stolze, Juliette; Teepen, Jop C.; Raber-Durlacher, Judith E.; Loonen, Jacqueline J.; Kok, Judith L.; Tissing, Wim J. E.; de Vries, Andrica C. H.; Neggers, Sebastian J. C. M. M.; van Dulmen-den Broeder, Eline; van den Heuvel-Eibrink, Marry M.; van der Pal, Helena J. H.; Versluys, A. Birgitta; van der Heiden-van der Loo, Margriet; Louwerens, Marloes; Kremer, Leontien C. M.; Brand, Henk S.; Bresters, Dorine
- Abstract
Simple Summary: Salivary gland dysfunction is an underestimated late effect in childhood cancer survivors (CCS). The objective of this cross-sectional study, part of the multidisciplinary multicenter Dutch Childhood Cancer Survivor Study Late Effects 2 (DCCSS LATER 2), was to assess the prevalence of and risk factors for hyposalivation and xerostomia in CCS with a long-term follow-up exceeding 15 years. From February 2016 until March 2020, 292 CCS were included. The prevalence of hyposalivation was 32% and the prevalence of xerostomia was 9.4%. Hyposalivation and xerostomia did not correlate significantly. Risk factors for hyposalivation were female gender and a higher dose of radiotherapy (>12 Gy) to the salivary glands. Screening for hyposalivation during long-term follow-up in CCS is recommended in order to provide optimal oral supportive care aimed to improve oral health. Background: Limited data are available on the risk factors of salivary gland dysfunction in long-term childhood cancer survivors (CCS). The objective of this cross-sectional study, part of the multidisciplinary multicenter Dutch CCS Study Late Effects 2 (DCCSS LATER 2), was to assess the prevalence of and risk factors for hyposalivation and xerostomia in CCS. Methods: From February 2016 until March 2020, 292 CCS were included. Data with regard to gender, age at study, diagnosis, age at diagnosis, and treatment characteristics were collected, as well as the unstimulated (UWS) and stimulated whole salivary flow rate (SWS). Xerostomia was assessed with the Xerostomia Inventory (XI) questionnaire. Multivariable Poisson regression analyses were used to evaluate the association between potential risk factors and the occurrence of hyposalivation. Results: The minimum time between diagnosis and study enrollment was 15 years. The prevalence of hyposalivation was 32% and the prevalence of xerostomia was 9.4%. Hyposalivation and xerostomia were not significantly correlated. Risk factors for hyposalivation were female gender and a higher dose of radiotherapy (>12 Gy) to the salivary gland region. Conclusion: Considering the importance of saliva for oral health, screening for hyposalivation in CCS is suggested in order to provide optimal oral supportive care aimed to improve oral health.
- Subjects
RESEARCH; CROSS-sectional method; SALIVA; ORAL health; TUMORS in children; TREATMENT effectiveness; RISK assessment; CANCER patients; XEROSTOMIA; SURVIVAL analysis (Biometry); HEALTH care teams; QUESTIONNAIRES; DESCRIPTIVE statistics; SALIVARY gland diseases; POISSON distribution; DISEASE risk factors; CHILDREN
- Publication
Cancers, 2022, Vol 14, Issue 14, pN.PAG
- ISSN
2072-6694
- Publication type
Article
- DOI
10.3390/cancers14143379